RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:391

Classic Hodgkin lymphoma

high confidenceDisorder

Also known as: Classic Hodgkin disease

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

8,246

97.9th percentile

Trials

157

Interventional, condition-specific

Researchers

1,402

Distinct authors in sample

Gene link

KLHDC8B

Limited

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

Classical Hodgkin lymphoma (CHL) is a B-cell lymphoma characterized histologically by the presence of large mononuclear Hodgkin cells and multinucleated Reed-Sternberg (HRS) cells.

How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

classic Hodgkin disease · classical Hodgkin lymphoma · classical Hodgkin's lymphoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Limited — KLHDC8B

  2. LiteraturePresent

    8,246 matched papers (6,189 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    157 matched on ClinicalTrials.gov (35 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Possibly — only limited evidence so far for KLHDC8B.

GenCC classification: Limited.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

8,246

8,246 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

8,246 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

6,189 in the last 10 years · high confidence · 97.9th percentile (publications denominator)

Phrase hits: 8,246 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,402

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Molin D6 papers · 2026

    Department of Immunology, Genetics, and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala Akademiska Hospital, Uppsala, Sweden.

    Papers in Europe PMC
  2. 02
    Wang L6 papers · 2026

    Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

    Papers in Europe PMC
  3. 03
    Armand P5 papers · 2026

    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

    Papers in Europe PMC
  4. 04
    Kamper P5 papers · 2026

    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.

    Papers in Europe PMC
  5. 05
    Liu C5 papers · 2026

    Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

    Papers in Europe PMC
  6. 06
    Liu Y5 papers · 2026

    Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

    Papers in Europe PMC
  7. 07
    Ansell SM4 papers · 2026

    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN. Electronic address: Ansell.Stephen@mayo.edu.

    Papers in Europe PMC
  8. 08
    Herrera AF4 papers · 2026

    Department of Hematology and Department of Oncology, Duarte, California, USA.

    Papers in Europe PMC
  9. 09
    Kuruvilla J4 papers · 2026

    Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada. Electronic address: john.kuruvilla@uhn.ca.

    Papers in Europe PMC
  10. 10
    Li Z4 papers · 2026

    Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. lixixi616@sina.com.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

157

interventional trials for this specific condition

157 interventional trials matched this specific condition name; 35 currently recruiting in our sample.

Data as of 27 July 2026

157 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 99th percentile).

high confidence · 99th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

157 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

17 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Classic Hodgkin lymphoma" OR "Classic Hodgkin disease" OR "classical Hodgkin lymphoma" OR "classical Hodgkin's lymphoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Classic Hodgkin lymphoma" OR "Classic Hodgkin disease" OR "classical Hodgkin lymphoma" OR "classical Hodgkin's lymphoma" OR "KLHDC8B"

Recall-expansion terms: KLHDC8B

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 157 interventional · 17 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T13:40:51.225Z